Emma Hall

发表

Bundling as a branding tool for events in the performing arts: a case study in opera attendance

Wayne Binney, Julian Vieceli, John Hall, 2013 .

Varumärken och ägodelar i hemmet - en studie om svenska kvinnors förhållanden till varumärken och ägodelar i heminredningen

Emma Hall, Lena Leide, Erica Grafström, 2005 .

Intermittent Androgen Suppression for Rising PSA Level After Radiotherapy

Joseph L. Chin, Celestia S. Higano, Fred Saad, 2013 .

Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients.

Petra Seibold, Hubert Thierens, Alison M Dunning, 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer

Richard Stock, Matthew R. Sydes, Kyriaki Michailidou, 2016, EBioMedicine.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial.

Annie Gao, John Staffurth, Peter Kirkbride, 2012, The Lancet. Oncology.

Consensus Guidelines and Contouring Atlas for Pelvic Node Delineation in Prostate and Pelvic Node Intensity Modulated Radiation Therapy.

John Staffurth, Emma Hall, Helen McNair, 2015, International journal of radiation oncology, biology, physics.

Intermittent androgen suppression for rising PSA level after radiotherapy.

Fred Saad, Emma Hall, Graeme Duncan, 2012, The New England journal of medicine.

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

Wei Yuan, Nina Tunariu, Rosalind Eeles, 2015, The New England journal of medicine.

Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

Annie Gao, Clare Griffin, John Staffurth, 2015, The Lancet. Oncology.

Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial

Emma Hall, Kevin J Harrington, S. Bhide, 2011, The Lancet. Oncology.

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.

Mike Clarke, K Wheatley, A Riccardi, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical development of new drug–radiotherapy combinations

Richard A. Adams, Kevin J. Harrington, Maria A. Hawkins, 2016, Nature Reviews Clinical Oncology.

Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.

Emma Hall, Nicholas D James, R. Huddart, 2012, The New England journal of medicine.

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

Annie Gao, Clare Griffin, John Staffurth, 2016, The Lancet. Oncology.

A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1

Alison M Dunning, Ángel Carracedo, Emma Hall, 2014, Nature Genetics.